Actively Recruiting
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
Led by Cantonal Hospital Graubuenden · Updated on 2025-09-12
40
Participants Needed
2
Research Sites
56 weeks
Total Duration
On this page
Sponsors
C
Cantonal Hospital Graubuenden
Lead Sponsor
U
University of Zurich
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to better understand electrolyte handling in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin. Patients will be randomized into two groups and take Empagliflozin or a Placebo for 2 weeks with a wash-out period of 2 weeks. The primary outcome is tubular handling of the divalent ions calcium, phosphate and magnesium. Secondary outcomes include diuresis, safety and tolerability.
CONDITIONS
Official Title
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18-75 years old with ADPKD as defined by international criteria, treated at Cantonal Hospital Graubünden or University Hospital Zürich
- Able and willing to provide informed consent by signing
You will not qualify if you...
- Receiving renal replacement therapy or have had a kidney transplant
- Chronic kidney disease stage G4 with eGFR under 30 ml/min/1.73m2
- Under 18 years of age
- Diagnosis of type 1 diabetes
- Recurrent urinary tract infections with more than 3 antibiotic treatments or more than 1 hospitalization per year
- Uncontrolled high blood pressure with systolic BP over 180 mmHg
- Liver cirrhosis classified as Child Pugh B or C
- Unable or unwilling to stop certain medications during the study, including thiazide diuretics, carbonic anhydrase inhibitors, sodium bicarbonate, calcitriol, bisphosphonates, denosumab, or teriparatide
- Pregnant or breastfeeding women
- Known allergy to the study drug
- Unable to understand or follow the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University Hospital Zurich, Division of Nephrology
Zurich, Canton of Zurich, Switzerland, 8091
Actively Recruiting
2
Cantonal Hospital Graubuenden
Chur, Kanton Graubünden, Switzerland, 7000
Actively Recruiting
Research Team
P
Patrick Hofmann, MD
CONTACT
T
Thomas Fehr, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here